251
|
Scarpelli R, Sasso O, Piomelli D. A Double Whammy: Targeting Both Fatty Acid Amide Hydrolase (FAAH) and Cyclooxygenase (COX) To Treat Pain and Inflammation. ChemMedChem 2016; 11:1242-51. [PMID: 26486424 PMCID: PMC4840092 DOI: 10.1002/cmdc.201500395] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2015] [Indexed: 11/10/2022]
Abstract
Pain states that arise from non-resolving inflammation, such as inflammatory bowel disease or arthritis, pose an unusually difficult challenge for therapy because of the complexity and heterogeneity of their underlying mechanisms. It has been suggested that key nodes linking interactive pathogenic pathways of non-resolving inflammation might offer novel targets for the treatment of inflammatory pain. Nonsteroidal anti-inflammatory drugs (NSAIDs), which inhibit the cyclooxygenase (COX)-mediated production of pain- and inflammation-inducing prostanoids, are a common first-line treatment for this condition, but their use is limited by mechanism-based side effects. The endogenous levels of anandamide, an endocannabinoid mediator with analgesic and tissue-protective functions, are regulated by fatty acid amide hydrolase (FAAH). This review outlines the pharmacological and chemical rationale for the simultaneous inhibition of COX and FAAH activities with designed multitarget agents. Preclinical studies indicate that such agents may combine superior anti-inflammatory efficacy with reduced toxicity.
Collapse
Affiliation(s)
- Rita Scarpelli
- Department of Drug Discovery and Development, Fondazione Istituto Italiano di Tecnologia, via Morego 30, 16163, Genoa, Italy
| | - Oscar Sasso
- Department of Drug Discovery and Development, Fondazione Istituto Italiano di Tecnologia, via Morego 30, 16163, Genoa, Italy
| | - Daniele Piomelli
- Department of Drug Discovery and Development, Fondazione Istituto Italiano di Tecnologia, via Morego 30, 16163, Genoa, Italy.
- Departments of Anatomy and Neurobiology, Pharmacology and Biological Chemistry, University of California, Irvine, CA, 92697-4625, USA.
| |
Collapse
|
252
|
Poornima P, Kumar JD, Zhao Q, Blunder M, Efferth T. Network pharmacology of cancer: From understanding of complex interactomes to the design of multi-target specific therapeutics from nature. Pharmacol Res 2016; 111:290-302. [PMID: 27329331 DOI: 10.1016/j.phrs.2016.06.018] [Citation(s) in RCA: 127] [Impact Index Per Article: 15.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/21/2015] [Revised: 06/16/2016] [Accepted: 06/17/2016] [Indexed: 12/14/2022]
Abstract
Despite massive investments in drug research and development, the significant decline in the number of new drugs approved or translated to clinical use raises the question, whether single targeted drug discovery is the right approach. To combat complex systemic diseases that harbour robust biological networks such as cancer, single target intervention is proved to be ineffective. In such cases, network pharmacology approaches are highly useful, because they differ from conventional drug discovery by addressing the ability of drugs to target numerous proteins or networks involved in a disease. Pleiotropic natural products are one of the promising strategies due to their multi-targeting and due to lower side effects. In this review, we discuss the application of network pharmacology for cancer drug discovery. We provide an overview of the current state of knowledge on network pharmacology, focus on different technical approaches and implications for cancer therapy (e.g. polypharmacology and synthetic lethality), and illustrate the therapeutic potential with selected examples green tea polyphenolics, Eleutherococcus senticosus, Rhodiola rosea, and Schisandra chinensis). Finally, we present future perspectives on their plausible applications for diagnosis and therapy of cancer.
Collapse
Affiliation(s)
- Paramasivan Poornima
- School of Chemistry, Bangor University, Bangor, Gwynedd LL57 2DG, United Kingdom
| | - Jothi Dinesh Kumar
- Department of Cellular and Molecular Physiology, Institute of Translational Medicine, University of Liverpool, Liverpool L69 3BX, United Kingdom
| | - Qiaoli Zhao
- Department of Pharmaceutical Biology, Johannes Gutenberg University, Mainz, Germany
| | - Martina Blunder
- Department of Neuroscience, Biomedical Center, Uppsala University, Uppsala, Sweden and Brain Institute, Federal University of Rio Grande do Norte, UFRN, Natal, Brazil
| | - Thomas Efferth
- Department of Pharmaceutical Biology, Johannes Gutenberg University, Mainz, Germany.
| |
Collapse
|
253
|
Rampa A, Tarozzi A, Mancini F, Pruccoli L, Di Martino RMC, Gobbi S, Bisi A, De Simone A, Palomba F, Zaccheroni N, Belluti F. Naturally Inspired Molecules as Multifunctional Agents for Alzheimer's Disease Treatment. Molecules 2016; 21:molecules21050643. [PMID: 27196880 PMCID: PMC6274376 DOI: 10.3390/molecules21050643] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/23/2016] [Revised: 04/27/2016] [Accepted: 05/11/2016] [Indexed: 12/13/2022] Open
Abstract
Alzheimer’s disease (AD) has been defined as a multi-factorial disorder resulting from a complex array of networked cellular and molecular mechanisms. In particular, elevated levels of Aβ protein and its aggregation products in the presence of metal ions proved to be highly neurotoxic and therapeutic strategies aimed at preventing Aβ generation and oxidative stress may represent an effective approach for AD treatment. A recent paradigm for the treatment of complex diseases such as AD suggests the employment of multifunctional compounds, single chemical entities capable of simultaneously modulating different targets involved in the pathology. In this paper, the “pharmacophores combination” strategy was applied, connecting the main scaffold of the BACE-1 ligand 1 to that of the chalcone 2, as metal chelating pharmacophore, to obtain a small library of compounds. Conjugate 5 emerged as the most interesting derivative, proving to inhibit BACE-1 with low-micromolar potency, and showing neuroprotective effects. In particular, 5 proved to be able to protect from metal-associated oxidative stress by hampering intracellular Cu2+-induced ROS formation without any direct neurotoxic effect.
Collapse
Affiliation(s)
- Angela Rampa
- Department of Pharmacy and Biotechnology, Alma Mater Studiorum-University of Bologna, Via Belmeloro 6, 40126 Bologna, Italy.
| | - Andrea Tarozzi
- Department for Life Quality Studies, Alma Mater Studiorum-University of Bologna, Corso D'Augusto 237, 47921 Rimini, Italy.
| | - Francesca Mancini
- Department of Pharmacy and Biotechnology, Alma Mater Studiorum-University of Bologna, Via Belmeloro 6, 40126 Bologna, Italy.
| | - Letizia Pruccoli
- Department for Life Quality Studies, Alma Mater Studiorum-University of Bologna, Corso D'Augusto 237, 47921 Rimini, Italy.
| | - Rita Maria Concetta Di Martino
- Department of Pharmacy and Biotechnology, Alma Mater Studiorum-University of Bologna, Via Belmeloro 6, 40126 Bologna, Italy.
| | - Silvia Gobbi
- Department of Pharmacy and Biotechnology, Alma Mater Studiorum-University of Bologna, Via Belmeloro 6, 40126 Bologna, Italy.
| | - Alessandra Bisi
- Department of Pharmacy and Biotechnology, Alma Mater Studiorum-University of Bologna, Via Belmeloro 6, 40126 Bologna, Italy.
| | - Angela De Simone
- Department for Life Quality Studies, Alma Mater Studiorum-University of Bologna, Corso D'Augusto 237, 47921 Rimini, Italy.
| | - Francesco Palomba
- Department of Chemistry ''G. Ciamician'', Alma Mater Studiorum-University of Bologna, Via Selmi 2, 40126 Bologna, Italy.
| | - Nelsi Zaccheroni
- Department of Chemistry ''G. Ciamician'', Alma Mater Studiorum-University of Bologna, Via Selmi 2, 40126 Bologna, Italy.
| | - Federica Belluti
- Department of Pharmacy and Biotechnology, Alma Mater Studiorum-University of Bologna, Via Belmeloro 6, 40126 Bologna, Italy.
| |
Collapse
|
254
|
Tan Z, Chaudhai R, Zhang S. Polypharmacology in Drug Development: A Minireview of Current Technologies. ChemMedChem 2016; 11:1211-8. [PMID: 27154144 DOI: 10.1002/cmdc.201600067] [Citation(s) in RCA: 32] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2016] [Revised: 03/21/2016] [Indexed: 01/09/2023]
Abstract
Polypharmacology, the process in which a single drug is able to bind to multiple targets specifically and simultaneously, is an emerging paradigm in drug development. The potency of a given drug can be increased through the engagement of multiple targets involved in a certain disease. Polypharmacology may also help identify novel applications of existing drugs through drug repositioning. However, many problems and challenges remain in this field. Rather than covering all aspects of polypharmacology, this Minireview is focused primarily on recently reported techniques, from bioinformatics technologies to cheminformatics approaches as well as text-mining-based methods, all of which have made significant contributions to the research of polypharmacology.
Collapse
Affiliation(s)
- Zhi Tan
- Integrated Molecular Discovery Laboratory, Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.,The University of Texas Graduate School of Biomedical Sciences, Houston, TX, 77030, USA
| | - Rajan Chaudhai
- Integrated Molecular Discovery Laboratory, Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA
| | - Shuxing Zhang
- Integrated Molecular Discovery Laboratory, Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA. .,The University of Texas Graduate School of Biomedical Sciences, Houston, TX, 77030, USA.
| |
Collapse
|
255
|
Prati F, Cavalli A, Bolognesi ML. Navigating the Chemical Space of Multitarget-Directed Ligands: From Hybrids to Fragments in Alzheimer's Disease. Molecules 2016; 21:466. [PMID: 27070562 PMCID: PMC6273289 DOI: 10.3390/molecules21040466] [Citation(s) in RCA: 77] [Impact Index Per Article: 9.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2016] [Revised: 04/03/2016] [Accepted: 04/05/2016] [Indexed: 12/15/2022] Open
Abstract
Multitarget drug discovery is one of the hottest topics and most active fields in the search for new molecules against Alzheimer’s disease (AD). Over the last 20 years, many promising multitarget-directed ligands (MTDLs) have been identified and developed at a pre-clinical level. However, how to design them in a rational way remains the most fundamental challenge of medicinal chemists. This is related to the foundational question of achieving an optimized activity towards multiple targets of interest, while preserving drug-like properties. In this respect, large hybrid molecules and small fragments are poles apart. In this review article, our aim is to appraise what we have accomplished in the development of both hybrid- and fragment-like molecules directed to diverse AD targets (i.e., acetylcholinesterase, NMDA receptors, metal chelation, BACE-1 and GSK-3β). In addition, we attempt to highlight what are the persistent needs that deserve to be improved and cared for, with the ultimate goal of moving an MTDL to AD clinical studies.
Collapse
Affiliation(s)
- Federica Prati
- Department of Pharmacy and Biotechnology, Alma Mater Studiorum-University of Bologna, Via Belmeloro 6, I-40126 Bologna, Italy.
- Sir James Black Centre, College of Life Sciences, University of Dundee, Dundee DD1 5EH, UK.
| | - Andrea Cavalli
- Department of Pharmacy and Biotechnology, Alma Mater Studiorum-University of Bologna, Via Belmeloro 6, I-40126 Bologna, Italy.
- Department of Drug Discovery and Development, Istituto Italiano di Tecnologia, Via Morego 30, 16163 Genova, Italy.
| | - Maria Laura Bolognesi
- Department of Pharmacy and Biotechnology, Alma Mater Studiorum-University of Bologna, Via Belmeloro 6, I-40126 Bologna, Italy.
| |
Collapse
|
256
|
Hebda M, Bajda M, Więckowska A, Szałaj N, Pasieka A, Panek D, Godyń J, Wichur T, Knez D, Gobec S, Malawska B. Synthesis, Molecular Modelling and Biological Evaluation of Novel Heterodimeric, Multiple Ligands Targeting Cholinesterases and Amyloid Beta. Molecules 2016; 21:410. [PMID: 27023510 PMCID: PMC6273065 DOI: 10.3390/molecules21040410] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/27/2016] [Revised: 03/17/2016] [Accepted: 03/23/2016] [Indexed: 02/03/2023] Open
Abstract
Cholinesterases and amyloid beta are one of the major biological targets in the search for a new and efficacious treatment of Alzheimer's disease. The study describes synthesis and pharmacological evaluation of new compounds designed as dual binding site acetylcholinesterase inhibitors. Among the synthesized compounds, two deserve special attention--compounds 42 and 13. The former is a saccharin derivative and the most potent and selective acetylcholinesterase inhibitor (EeAChE IC50 = 70 nM). Isoindoline-1,3-dione derivative 13 displays balanced inhibitory potency against acetyl- and butyrylcholinesterase (BuChE) (EeAChE IC50 = 0.76 μM, EqBuChE IC50 = 0.618 μM), and it inhibits amyloid beta aggregation (35.8% at 10 μM). Kinetic studies show that the developed compounds act as mixed or non-competitive acetylcholinesterase inhibitors. According to molecular modelling studies, they are able to interact with both catalytic and peripheral active sites of the acetylcholinesterase. Their ability to cross the blood-brain barrier (BBB) was confirmed in vitro in the parallel artificial membrane permeability BBB assay. These compounds can be used as a solid starting point for further development of novel multifunctional ligands as potential anti-Alzheimer's agents.
Collapse
Affiliation(s)
- Michalina Hebda
- Department of Physicochemical Drug Analysis, Faculty of Pharmacy, Jagiellonian University Medical College, Kraków 30-688, Poland.
| | - Marek Bajda
- Department of Physicochemical Drug Analysis, Faculty of Pharmacy, Jagiellonian University Medical College, Kraków 30-688, Poland.
| | - Anna Więckowska
- Department of Physicochemical Drug Analysis, Faculty of Pharmacy, Jagiellonian University Medical College, Kraków 30-688, Poland.
| | - Natalia Szałaj
- Department of Physicochemical Drug Analysis, Faculty of Pharmacy, Jagiellonian University Medical College, Kraków 30-688, Poland.
| | - Anna Pasieka
- Department of Physicochemical Drug Analysis, Faculty of Pharmacy, Jagiellonian University Medical College, Kraków 30-688, Poland.
| | - Dawid Panek
- Department of Physicochemical Drug Analysis, Faculty of Pharmacy, Jagiellonian University Medical College, Kraków 30-688, Poland.
| | - Justyna Godyń
- Department of Physicochemical Drug Analysis, Faculty of Pharmacy, Jagiellonian University Medical College, Kraków 30-688, Poland.
| | - Tomasz Wichur
- Department of Physicochemical Drug Analysis, Faculty of Pharmacy, Jagiellonian University Medical College, Kraków 30-688, Poland.
| | - Damijan Knez
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Ljubljana, Ljubljana 1000, Slovenia.
| | - Stanislav Gobec
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Ljubljana, Ljubljana 1000, Slovenia.
| | - Barbara Malawska
- Department of Physicochemical Drug Analysis, Faculty of Pharmacy, Jagiellonian University Medical College, Kraków 30-688, Poland.
| |
Collapse
|
257
|
Camilleri M, Bueno L, Andresen V, De Ponti F, Choi MG, Lembo A. Pharmacological, Pharmacokinetic, and Pharmacogenomic Aspects of Functional Gastrointestinal Disorders. Gastroenterology 2016; 150:S0016-5085(16)00220-1. [PMID: 27144621 DOI: 10.1053/j.gastro.2016.02.029] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/03/2016] [Accepted: 02/09/2016] [Indexed: 02/08/2023]
Abstract
This article reviews medications commonly used for the treatment of patients with functional gastrointestinal disorders. Specifically, we review the animal models that have been validated for the study of drug effects on sensation and motility; the preclinical pharmacology, pharmacokinetics, and toxicology usually required for introduction of new drugs; the biomarkers that are validated for studies of sensation and motility endpoints with experimental medications in humans; the pharmacogenomics applied to these medications and their relevance to the FGIDs; and the pharmacology of agents that are applied or have potential for the treatment of FGIDs, including psychopharmacologic drugs.
Collapse
Affiliation(s)
- Michael Camilleri
- Professor of Medicine, Pharmacology, and Physiology, Mayo Clinic College of Medicine, Consultant in Gastroenterology, Mayo Clinic, Rochester, Minnesota, USA
| | | | - Viola Andresen
- Israelitic Hospital, University of Hamburg, Orchideenstieg 14, Hamburg, Germany
| | - Fabrizio De Ponti
- Professor of Pharmacology, Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy
| | - Myung-Gyu Choi
- Professor of Gastroenterology, The Catholic University of Korea College of Medicine Internal Medicine , President, Korean Society of Neurogastroenterology and Motility , Seoul, Korea
| | - Anthony Lembo
- Associate Professor, Harvard Medical School, Director of the GI Motility Laboratory at the Beth Israel Deaconess Medical Center's (BIDMC) Division of Gastroenterology, Boston, MA, USA
| |
Collapse
|
258
|
New hybrid molecules with anticonvulsant and antinociceptive activity derived from 3-methyl- or 3,3-dimethyl-1-[1-oxo-1-(4-phenylpiperazin-1-yl)propan-2-yl]pyrrolidine-2,5-diones. Bioorg Med Chem 2016; 24:606-18. [DOI: 10.1016/j.bmc.2015.12.027] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2015] [Revised: 12/14/2015] [Accepted: 12/15/2015] [Indexed: 12/13/2022]
|
259
|
Éliás O, Nógrádi K, Domány G, Szakács Z, Kóti J, Szántay C, Tarcsay Á, Keserű GM, Gere A, Kiss B, Kurkó D, Kolok S, Némethy Z, Kapui Z, Hellinger É, Vastag M, Sághy K, Kedves R, Gyertyán I. The influence of 5-HT(2A) activity on a 5-HT(2C) specific in vivo assay used for early identification of multiple acting SERT and 5-HT(2C) receptor ligands. Bioorg Med Chem Lett 2016; 26:914-920. [PMID: 26748694 DOI: 10.1016/j.bmcl.2015.12.071] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/02/2015] [Revised: 12/18/2015] [Accepted: 12/19/2015] [Indexed: 11/16/2022]
Abstract
As a result of our exploratory programme aimed at elaborating dually acting compounds towards the serotonin (5-HT) transporter (SERT) and the 5-HT2C receptor a novel series of 3-amino-1-phenylpropoxy substituted diphenylureas was identified. From that collection two promising compounds (2 and 3) exhibiting highest 5-HT2C receptor affinity strongly inhibited the 5-HT2C receptor agonist 1-(3-chlorophenyl)piperazine (mCPP) induced hypomotility in mice. In further pursuance of that objective (2-aminoethyl)(benzyl)sulfamoyl diphenylureas and diphenylpiperazines have also been elaborated. Herein we report the synthesis of potent multiple-acting compounds from this new class. However, when two optimized representatives (6 and 14) possessing the desired in vitro profile were tested neither reduced the motor activity of mCPP treated animals. Comparative albeit limited in vitro structure-activity relationship (SAR) analysis and detailed in vivo studies are discussed and explanation for their intricate behaviour is proposed.
Collapse
Affiliation(s)
- Olivér Éliás
- Gedeon Richter Plc, Budapest 10, PO Box 27, H-1475, Hungary
| | | | - György Domány
- Gedeon Richter Plc, Budapest 10, PO Box 27, H-1475, Hungary
| | - Zoltán Szakács
- Gedeon Richter Plc, Budapest 10, PO Box 27, H-1475, Hungary
| | - János Kóti
- Gedeon Richter Plc, Budapest 10, PO Box 27, H-1475, Hungary
| | - Csaba Szántay
- Gedeon Richter Plc, Budapest 10, PO Box 27, H-1475, Hungary
| | - Ákos Tarcsay
- Gedeon Richter Plc, Budapest 10, PO Box 27, H-1475, Hungary
| | - György M Keserű
- Research Centre for Natural Sciences, Hungarian Academy of Sciences, Budapest, PO Box 286, H-1519, Hungary
| | - Anikó Gere
- Gedeon Richter Plc, Budapest 10, PO Box 27, H-1475, Hungary
| | - Béla Kiss
- Gedeon Richter Plc, Budapest 10, PO Box 27, H-1475, Hungary
| | - Dalma Kurkó
- Gedeon Richter Plc, Budapest 10, PO Box 27, H-1475, Hungary
| | - Sándor Kolok
- Gedeon Richter Plc, Budapest 10, PO Box 27, H-1475, Hungary
| | - Zsolt Némethy
- Gedeon Richter Plc, Budapest 10, PO Box 27, H-1475, Hungary
| | - Zoltán Kapui
- Gedeon Richter Plc, Budapest 10, PO Box 27, H-1475, Hungary
| | - Éva Hellinger
- Gedeon Richter Plc, Budapest 10, PO Box 27, H-1475, Hungary
| | - Mónika Vastag
- Gedeon Richter Plc, Budapest 10, PO Box 27, H-1475, Hungary
| | - Katalin Sághy
- Gedeon Richter Plc, Budapest 10, PO Box 27, H-1475, Hungary
| | - Rita Kedves
- Gedeon Richter Plc, Budapest 10, PO Box 27, H-1475, Hungary
| | - István Gyertyán
- Department of Pharmacology and Pharmacotherapy, Semmelweis University, Budapest, Nagyvárad tér 4, H-1089, Hungary
| |
Collapse
|
260
|
Di Martino RMC, De Simone A, Andrisano V, Bisignano P, Bisi A, Gobbi S, Rampa A, Fato R, Bergamini C, Perez DI, Martinez A, Bottegoni G, Cavalli A, Belluti F. Versatility of the Curcumin Scaffold: Discovery of Potent and Balanced Dual BACE-1 and GSK-3β Inhibitors. J Med Chem 2016; 59:531-44. [PMID: 26696252 DOI: 10.1021/acs.jmedchem.5b00894] [Citation(s) in RCA: 86] [Impact Index Per Article: 10.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
The multitarget approach has gained increasing acceptance as a useful tool to address complex and multifactorial maladies such as Alzheimer's disease (AD). The concurrent inhibition of the validated AD targets β-secretase (BACE-1) and glycogen synthase kinase-3β (GSK-3β) by attacking both β-amyloid and tau protein cascades has been identified as a promising AD therapeutic strategy. In our study, curcumin was identified as a lead compound for the simultaneous inhibition of both targets; therefore, synthetic efforts were dedicated to obtaining a small library of novel curcumin-based analogues, and a number of potent and balanced dual-target inhibitors were obtained. In particular, 2, 6, and 7 emerged as promising drug candidates endowed with neuroprotective potential and brain permeability. Notably, for some new compounds the symmetrical diketo and the β-keto-enol tautomeric forms were purposely isolated and tested in vitro, allowing us to gain insight into the key requirements for BACE-1 and GSK-3β inhibition.
Collapse
Affiliation(s)
- Rita Maria Concetta Di Martino
- Department of Pharmacy and Biotechnology, Alma Mater Studiorum - University of Bologna , Via Belmeloro 6, 40126 Bologna, Italy
| | - Angela De Simone
- Department for Life Quality Studies, Alma Mater Studiorum - University of Bologna , Corso D'Augusto 237, 47921 Rimini, Italy
| | - Vincenza Andrisano
- Department for Life Quality Studies, Alma Mater Studiorum - University of Bologna , Corso D'Augusto 237, 47921 Rimini, Italy
| | - Paola Bisignano
- Istituto Italiano di Tecnologia , D3, via Morego 30, 16163 Genova, Italy
| | - Alessandra Bisi
- Department of Pharmacy and Biotechnology, Alma Mater Studiorum - University of Bologna , Via Belmeloro 6, 40126 Bologna, Italy
| | - Silvia Gobbi
- Department of Pharmacy and Biotechnology, Alma Mater Studiorum - University of Bologna , Via Belmeloro 6, 40126 Bologna, Italy
| | - Angela Rampa
- Department of Pharmacy and Biotechnology, Alma Mater Studiorum - University of Bologna , Via Belmeloro 6, 40126 Bologna, Italy
| | - Romana Fato
- Department of Pharmacy and Biotechnology, Alma Mater Studiorum - University of Bologna , Via Belmeloro 6, 40126 Bologna, Italy
| | - Christian Bergamini
- Department of Pharmacy and Biotechnology, Alma Mater Studiorum - University of Bologna , Via Belmeloro 6, 40126 Bologna, Italy
| | - Daniel I Perez
- Centro de Investigaciones Biologicas, CSIC , Ramiro de Maetzu 9, 28040 Madrid, Spain
| | - Ana Martinez
- Centro de Investigaciones Biologicas, CSIC , Ramiro de Maetzu 9, 28040 Madrid, Spain
| | - Giovanni Bottegoni
- Istituto Italiano di Tecnologia , D3, via Morego 30, 16163 Genova, Italy
| | - Andrea Cavalli
- Department of Pharmacy and Biotechnology, Alma Mater Studiorum - University of Bologna , Via Belmeloro 6, 40126 Bologna, Italy.,Istituto Italiano di Tecnologia , D3, via Morego 30, 16163 Genova, Italy
| | - Federica Belluti
- Department of Pharmacy and Biotechnology, Alma Mater Studiorum - University of Bologna , Via Belmeloro 6, 40126 Bologna, Italy
| |
Collapse
|
261
|
Golestanian S, Sharifi A, Popowicz GM, Azizian H, Foroumadi A, Szwagierczak A, Holak TA, Amanlou M. Discovery of novel dual inhibitors against Mdm2 and Mdmx proteins by in silico approaches and binding assay. Life Sci 2016; 145:240-6. [DOI: 10.1016/j.lfs.2015.12.047] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/02/2015] [Revised: 12/26/2015] [Accepted: 12/29/2015] [Indexed: 11/26/2022]
|
262
|
|
263
|
Kushwaha PS, Singh AK, Keshari AK, Maity S, Saha S. An Updated Review on the Phytochemistry, Pharmacology, and Clinical Trials of Salacia oblonga. Pharmacogn Rev 2016; 10:109-114. [PMID: 28082793 PMCID: PMC5214554 DOI: 10.4103/0973-7847.194046] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Abstract
Salacia oblonga (S. oblonga), a perennial herb, has been used for thousands of years in ayurvedic medicine and is closely associated with prevention, treatment, and cure of various human ailments such as obesity and diabetes. A vast and wide range of chemical compounds such as polyphenols, friedelane-type triterpenes, norfriedelane-type triterpenes, eudesmane-type sesquiterpenes including various glycosides had been isolated from this plant. This review is aimed to survey the literature covering the phytochemistry and pharmacology of S. oblonga and to review the scientific data including active components and their multi-targeted mechanisms of action against various metabolic syndromes. We also included clinical trials related to this plant in this review. The overview would assist researchers to gather scientific information related to S. oblonga in future.
Collapse
Affiliation(s)
- Priya Singh Kushwaha
- Department of Pharmaceutical Sciences, Babasaheb Bhimrao Ambedkar University, Lucknow, Uttar Pradesh, India
| | - Ashok K Singh
- Department of Pharmaceutical Sciences, Babasaheb Bhimrao Ambedkar University, Lucknow, Uttar Pradesh, India
| | - Amit K Keshari
- Department of Pharmaceutical Sciences, Babasaheb Bhimrao Ambedkar University, Lucknow, Uttar Pradesh, India
| | - Siddhartha Maity
- Department of Pharmaceutical Technology, Jadavpur University, Kolkata, West Bengal, India
| | - Sudipta Saha
- Department of Pharmaceutical Sciences, Babasaheb Bhimrao Ambedkar University, Lucknow, Uttar Pradesh, India
| |
Collapse
|
264
|
Idowu T, Samadder P, Arthur G, Schweizer F. Design, synthesis and antitumor properties of glycosylated antitumor ether lipid (GAEL)- chlorambucil-hybrids. Chem Phys Lipids 2016; 194:139-48. [DOI: 10.1016/j.chemphyslip.2015.07.003] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/01/2015] [Revised: 07/07/2015] [Accepted: 07/08/2015] [Indexed: 12/23/2022]
|
265
|
Deekonda S, Cole J, Sunna S, Rankin D, Largent-Milnes TM, Davis P, BassiriRad NM, Lai J, Vanderah TW, Porecca F, Hruby VJ. Enkephalin analogues with N-phenyl-N-(piperidin-2-ylmethyl)propionamide derivatives: Synthesis and biological evaluations. Bioorg Med Chem Lett 2016; 26:222-7. [PMID: 26611918 PMCID: PMC4873255 DOI: 10.1016/j.bmcl.2015.10.081] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2015] [Revised: 10/21/2015] [Accepted: 10/26/2015] [Indexed: 11/30/2022]
Abstract
N-Phenyl-N-(piperidin-2-ylmethyl)propionamide based bivalent ligands are unexplored for the design of opioid based ligands. Two series of hybrid molecules bearing N-phenyl-N-(piperidin-2-ylmethyl)propionamide derived small molecules conjugated with an enkephalin analogues with and without a linker (β-alanine) were designed and synthesized. Both bivalent ligand series exhibited remarkable binding affinities from nanomolar to subnanomolar range at both μ and δ opioid receptors and displayed potent agonist activities as well. The replacement of Tyr with Dmt and introduction of a linker between the small molecule and enkephalin analogue resulted in highly potent ligands. Both series of ligands showed excellent binding affinities at both μ (0.6-0.9nM) and δ (0.2-1.2nM) opioid receptors respectively. Similarly, these bivalent ligands exhibited potent agonist activities in both MVD and GPI assays. Ligand 17 was evaluated for in vivo antinociceptive activity in non-injured rats following spinal administration. Ligand 17 was not significantly effective in alleviating acute pain. The most likely explanations for this low intrinsic efficacy in vivo despite high in vitro binding affinity, moderate in vitro activity are (i) low potency suggesting that higher doses are needed; (ii) differences in experimental design (i.e. non-neuronal, high receptor density for in vitro preparations versus CNS site of action in vitro); (iii) pharmacodynamics (i.e. engaging signalling pathways); (iv) pharmacokinetics (i.e. metabolic stability). In summary, our data suggest that further optimisation of this compound 17 is required to enhance intrinsic antinociceptive efficacy.
Collapse
Affiliation(s)
- Srinivas Deekonda
- Department of Chemistry and Biochemistry, University of Arizona, Tucson, AZ 85721, United States
| | - Jacob Cole
- Department of Chemistry and Biochemistry, University of Arizona, Tucson, AZ 85721, United States
| | - Sydney Sunna
- Department of Chemistry and Biochemistry, University of Arizona, Tucson, AZ 85721, United States
| | - David Rankin
- Department of Pharmacology, University of Arizona, Tucson, AZ 85721, United States
| | | | - Peg Davis
- Department of Pharmacology, University of Arizona, Tucson, AZ 85721, United States
| | - Neemah M BassiriRad
- Department of Pharmacology, University of Arizona, Tucson, AZ 85721, United States
| | - Josephine Lai
- Department of Pharmacology, University of Arizona, Tucson, AZ 85721, United States
| | - Todd W Vanderah
- Department of Pharmacology, University of Arizona, Tucson, AZ 85721, United States
| | - Frank Porecca
- Department of Pharmacology, University of Arizona, Tucson, AZ 85721, United States
| | - Victor J Hruby
- Department of Chemistry and Biochemistry, University of Arizona, Tucson, AZ 85721, United States.
| |
Collapse
|
266
|
Bottegoni G, Veronesi M, Bisignano P, Kacker P, Favia AD, Cavalli A. Development and Application of a Virtual Screening Protocol for the Identification of Multitarget Fragments. ChemMedChem 2015; 11:1259-63. [PMID: 26663255 DOI: 10.1002/cmdc.201500521] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2015] [Indexed: 11/09/2022]
Abstract
In this study, we report on a virtual ligand screening protocol optimized to identify fragments endowed with activity at multiple targets. Thanks to this protocol, we were able to identify a fragment that displays activity in the low-micromolar range at both β-secretase 1 (BACE-1) and glycogen synthase kinase 3β (GSK-3β). These two structurally and physiologically unrelated enzymes likely contribute, through different pathways, to the onset of Alzheimer's disease (AD). Therefore, their simultaneous inhibition holds great potential in exerting a profound effect on AD. In perspective, the strategy outlined herein can be adapted to other target combinations.
Collapse
Affiliation(s)
- Giovanni Bottegoni
- CompuNet, Istituto Italiano di Tecnologia, 16163, Genova, Italy. .,BiKi Technologies srl, 16121, Genova, Italy.
| | - Marina Veronesi
- PharmaChemistry Facility, Istituto Italiano di Tecnologia, 16163, Genova, Italy
| | - Paola Bisignano
- Department of Pharmaceutical Chemistry, Cardiovascular Research Institute, University of California, San Francisco, CA, 94158, USA
| | - Puneet Kacker
- Drug Repurposing Division, GVK Biosciences Pvt. Ltd., 500076, Hyderabad, India
| | - Angelo D Favia
- CompuNet, Istituto Italiano di Tecnologia, 16163, Genova, Italy
| | - Andrea Cavalli
- CompuNet, Istituto Italiano di Tecnologia, 16163, Genova, Italy.,FaBit, University of Bologna, 40126, Bologna, Italy
| |
Collapse
|
267
|
Mendoza-Sanchez R, Cotnoir-White D, Kulpa J, Jutras I, Pottel J, Moitessier N, Mader S, Gleason JL. Design, synthesis and evaluation of antiestrogen and histone deacetylase inhibitor molecular hybrids. Bioorg Med Chem 2015; 23:7597-606. [DOI: 10.1016/j.bmc.2015.11.005] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/20/2015] [Revised: 10/28/2015] [Accepted: 11/05/2015] [Indexed: 01/28/2023]
|
268
|
Theodosis-Nobelos P, Kourti M, Tziona P, Kourounakis PN, Rekka EA. Esters of some non-steroidal anti-inflammatory drugs with cinnamyl alcohol are potent lipoxygenase inhibitors with enhanced anti-inflammatory activity. Bioorg Med Chem Lett 2015; 25:5028-31. [PMID: 26494261 DOI: 10.1016/j.bmcl.2015.10.036] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2015] [Revised: 10/12/2015] [Accepted: 10/13/2015] [Indexed: 11/20/2022]
Abstract
Novel esters of non steroidal anti-inflammatory drugs, α-lipoic acid and indol-3-acetic acid with cinnamyl alcohol were synthesised by a straightforward method and at high yields (60-98%). They reduced acute inflammation more than the parent acids and are potent inhibitors of soybean lipoxygenase. Selected structures decreased plasma lipidemic indices in Triton-induced hyperlipidemia to rats. Therefore, the synthesised compounds may add to the current knowledge about agents acting against various inflammatory disorders.
Collapse
Affiliation(s)
- Panagiotis Theodosis-Nobelos
- Department of Pharmaceutical Chemistry, School of Pharmacy, Aristotelian University of Thessaloniki, Thessaloniki 54124, Greece
| | - Malamati Kourti
- Department of Pharmaceutical Chemistry, School of Pharmacy, Aristotelian University of Thessaloniki, Thessaloniki 54124, Greece
| | - Paraskevi Tziona
- Department of Pharmaceutical Chemistry, School of Pharmacy, Aristotelian University of Thessaloniki, Thessaloniki 54124, Greece
| | - Panos N Kourounakis
- Department of Pharmaceutical Chemistry, School of Pharmacy, Aristotelian University of Thessaloniki, Thessaloniki 54124, Greece
| | - Eleni A Rekka
- Department of Pharmaceutical Chemistry, School of Pharmacy, Aristotelian University of Thessaloniki, Thessaloniki 54124, Greece.
| |
Collapse
|
269
|
Nepovimova E, Korabecny J, Dolezal R, Babkova K, Ondrejicek A, Jun D, Sepsova V, Horova A, Hrabinova M, Soukup O, Bukum N, Jost P, Muckova L, Kassa J, Malinak D, Andrs M, Kuca K. Tacrine–Trolox Hybrids: A Novel Class of Centrally Active, Nonhepatotoxic Multi-Target-Directed Ligands Exerting Anticholinesterase and Antioxidant Activities with Low In Vivo Toxicity. J Med Chem 2015; 58:8985-9003. [DOI: 10.1021/acs.jmedchem.5b01325] [Citation(s) in RCA: 103] [Impact Index Per Article: 11.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Affiliation(s)
- Eugenie Nepovimova
- Biomedical
Research Centre, University Hospital Hradec Kralove, Sokolska 581, 500 05 Hradec Kralove, Czech Republic
- Department
of Toxicology and Military Pharmacy, Faculty of Military Health Sciences, University of Defence, Trebesska 1575, 500 01 Hradec Kralove, Czech Republic
- Department
of Intensive Medicine and Forensic Studies; Department of Physiology
and Pathophysiology, Faculty of Medicine, University of Ostrava, Syllabova 19, 703 00 Ostrava, Czech Republic
| | - Jan Korabecny
- Biomedical
Research Centre, University Hospital Hradec Kralove, Sokolska 581, 500 05 Hradec Kralove, Czech Republic
- Department
of Toxicology and Military Pharmacy, Faculty of Military Health Sciences, University of Defence, Trebesska 1575, 500 01 Hradec Kralove, Czech Republic
- National Institute of Mental Health, Topolova 748, 250 67 Klecany, Czech Republic
| | - Rafael Dolezal
- Biomedical
Research Centre, University Hospital Hradec Kralove, Sokolska 581, 500 05 Hradec Kralove, Czech Republic
| | - Katerina Babkova
- Biomedical
Research Centre, University Hospital Hradec Kralove, Sokolska 581, 500 05 Hradec Kralove, Czech Republic
- Department
of Toxicology and Military Pharmacy, Faculty of Military Health Sciences, University of Defence, Trebesska 1575, 500 01 Hradec Kralove, Czech Republic
| | - Ales Ondrejicek
- Department
of Pharmaceutical Chemistry and Drug Control, Faculty of Pharmacy
in Hradec Kralove, Charles University in Prague, Heyrovskeho 1203, 500 05 Hradec Kralove, Czech Republic
| | - Daniel Jun
- Biomedical
Research Centre, University Hospital Hradec Kralove, Sokolska 581, 500 05 Hradec Kralove, Czech Republic
- Department
of Toxicology and Military Pharmacy, Faculty of Military Health Sciences, University of Defence, Trebesska 1575, 500 01 Hradec Kralove, Czech Republic
| | - Vendula Sepsova
- Biomedical
Research Centre, University Hospital Hradec Kralove, Sokolska 581, 500 05 Hradec Kralove, Czech Republic
- Department
of Toxicology and Military Pharmacy, Faculty of Military Health Sciences, University of Defence, Trebesska 1575, 500 01 Hradec Kralove, Czech Republic
| | - Anna Horova
- Biomedical
Research Centre, University Hospital Hradec Kralove, Sokolska 581, 500 05 Hradec Kralove, Czech Republic
- Department
of Toxicology and Military Pharmacy, Faculty of Military Health Sciences, University of Defence, Trebesska 1575, 500 01 Hradec Kralove, Czech Republic
| | - Martina Hrabinova
- Biomedical
Research Centre, University Hospital Hradec Kralove, Sokolska 581, 500 05 Hradec Kralove, Czech Republic
- Department
of Toxicology and Military Pharmacy, Faculty of Military Health Sciences, University of Defence, Trebesska 1575, 500 01 Hradec Kralove, Czech Republic
| | - Ondrej Soukup
- Biomedical
Research Centre, University Hospital Hradec Kralove, Sokolska 581, 500 05 Hradec Kralove, Czech Republic
- Department
of Toxicology and Military Pharmacy, Faculty of Military Health Sciences, University of Defence, Trebesska 1575, 500 01 Hradec Kralove, Czech Republic
- National Institute of Mental Health, Topolova 748, 250 67 Klecany, Czech Republic
| | - Neslihan Bukum
- Biomedical
Research Centre, University Hospital Hradec Kralove, Sokolska 581, 500 05 Hradec Kralove, Czech Republic
| | - Petr Jost
- Biomedical
Research Centre, University Hospital Hradec Kralove, Sokolska 581, 500 05 Hradec Kralove, Czech Republic
- Department
of Toxicology and Military Pharmacy, Faculty of Military Health Sciences, University of Defence, Trebesska 1575, 500 01 Hradec Kralove, Czech Republic
| | - Lubica Muckova
- Department
of Toxicology and Military Pharmacy, Faculty of Military Health Sciences, University of Defence, Trebesska 1575, 500 01 Hradec Kralove, Czech Republic
| | - Jiri Kassa
- Department
of Toxicology and Military Pharmacy, Faculty of Military Health Sciences, University of Defence, Trebesska 1575, 500 01 Hradec Kralove, Czech Republic
| | - David Malinak
- Biomedical
Research Centre, University Hospital Hradec Kralove, Sokolska 581, 500 05 Hradec Kralove, Czech Republic
- Department
of Intensive Medicine and Forensic Studies; Department of Physiology
and Pathophysiology, Faculty of Medicine, University of Ostrava, Syllabova 19, 703 00 Ostrava, Czech Republic
| | - Martin Andrs
- Biomedical
Research Centre, University Hospital Hradec Kralove, Sokolska 581, 500 05 Hradec Kralove, Czech Republic
- Department
of Toxicology and Military Pharmacy, Faculty of Military Health Sciences, University of Defence, Trebesska 1575, 500 01 Hradec Kralove, Czech Republic
| | - Kamil Kuca
- Biomedical
Research Centre, University Hospital Hradec Kralove, Sokolska 581, 500 05 Hradec Kralove, Czech Republic
| |
Collapse
|
270
|
Dolles D, Nimczick M, Scheiner M, Ramler J, Stadtmüller P, Sawatzky E, Drakopoulos A, Sotriffer C, Wittmann HJ, Strasser A, Decker M. Aminobenzimidazoles and Structural Isomers as Templates for Dual-Acting Butyrylcholinesterase Inhibitors andhCB2R Ligands To Combat Neurodegenerative Disorders. ChemMedChem 2015; 11:1270-83. [DOI: 10.1002/cmdc.201500418] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2015] [Indexed: 11/12/2022]
Affiliation(s)
- Dominik Dolles
- Pharmaceutical and Medicinal Chemistry; Institute of Pharmacy and Food Chemistry; Julius-Maximilians-Universität Würzburg; Am Hubland 97074 Würzburg Germany
| | - Martin Nimczick
- Pharmaceutical and Medicinal Chemistry; Institute of Pharmacy and Food Chemistry; Julius-Maximilians-Universität Würzburg; Am Hubland 97074 Würzburg Germany
| | - Matthias Scheiner
- Pharmaceutical and Medicinal Chemistry; Institute of Pharmacy and Food Chemistry; Julius-Maximilians-Universität Würzburg; Am Hubland 97074 Würzburg Germany
| | - Jacqueline Ramler
- Pharmaceutical and Medicinal Chemistry; Institute of Pharmacy and Food Chemistry; Julius-Maximilians-Universität Würzburg; Am Hubland 97074 Würzburg Germany
| | - Patricia Stadtmüller
- Pharmaceutical and Medicinal Chemistry; Institute of Pharmacy and Food Chemistry; Julius-Maximilians-Universität Würzburg; Am Hubland 97074 Würzburg Germany
| | - Edgar Sawatzky
- Pharmaceutical and Medicinal Chemistry; Institute of Pharmacy and Food Chemistry; Julius-Maximilians-Universität Würzburg; Am Hubland 97074 Würzburg Germany
| | - Antonios Drakopoulos
- Pharmaceutical and Medicinal Chemistry; Institute of Pharmacy and Food Chemistry; Julius-Maximilians-Universität Würzburg; Am Hubland 97074 Würzburg Germany
| | - Christoph Sotriffer
- Pharmaceutical and Medicinal Chemistry; Institute of Pharmacy and Food Chemistry; Julius-Maximilians-Universität Würzburg; Am Hubland 97074 Würzburg Germany
| | - Hans-Joachim Wittmann
- Pharmaceutical and Medicinal Chemistry II; Institute of Pharmacy; University of Regensburg; 95053 Regensburg Germany
| | - Andrea Strasser
- Pharmaceutical and Medicinal Chemistry II; Institute of Pharmacy; University of Regensburg; 95053 Regensburg Germany
| | - Michael Decker
- Pharmaceutical and Medicinal Chemistry; Institute of Pharmacy and Food Chemistry; Julius-Maximilians-Universität Würzburg; Am Hubland 97074 Würzburg Germany
| |
Collapse
|
271
|
Jadhav SB, Fatema S, Farooqui M. WITHDRAWN: Tetra-block conjugates: Synthesis and pharmacological evaluation of thiazolo[3,2-a]pyrimidinones as dual inhibitor of tuberculosis and inflammation. Bioorg Med Chem Lett 2015. [DOI: 10.1016/j.bmcl.2015.11.020] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
272
|
Lin JH. Review structure- and dynamics-based computational design of anticancer drugs. Biopolymers 2015; 105:2-9. [DOI: 10.1002/bip.22744] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/2015] [Revised: 09/16/2015] [Accepted: 09/16/2015] [Indexed: 01/13/2023]
Affiliation(s)
- Jung Hsin Lin
- Research Center for Applied Sciences, Academia Sinica; Taipei Taiwan
- Institute of Biomedical Sciences, Academia Sinica; Taipei Taiwan
- School of Pharmacy; National Taiwan University; Taipei Taiwan
| |
Collapse
|
273
|
Mátyus P, Chai CLL. Metabolism-Activated Multitargeting (MAMUT): An Innovative Multitargeting Approach to Drug Design and Development. ChemMedChem 2015; 11:1197-8. [DOI: 10.1002/cmdc.201500406] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/07/2015] [Indexed: 11/09/2022]
Affiliation(s)
- Péter Mátyus
- Bionics Innovation Center (Hungary)
- Department of Organic Chemistry; Semmelweis University; Hőgyes E. u. 7 1092 Budapest Hungary
| | - Christina L. L. Chai
- Department of Pharmacy; Faculty of Science; National University of Singapore; 18 Science Drive 4 Singapore 117543 Singapore
| |
Collapse
|
274
|
Sharma S, Gupta MK, Saxena AK, Bedi PMS. Triazole linked mono carbonyl curcumin-isatin bifunctional hybrids as novel anti tubulin agents: Design, synthesis, biological evaluation and molecular modeling studies. Bioorg Med Chem 2015; 23:7165-80. [PMID: 26515041 DOI: 10.1016/j.bmc.2015.10.013] [Citation(s) in RCA: 46] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/18/2015] [Revised: 10/06/2015] [Accepted: 10/11/2015] [Indexed: 12/13/2022]
Abstract
Keeping in view the limitations associated with currently available anticancer drugs, molecular hybrids of mono carbonyl curcumin and isatin tethered by triazole ring have been synthesized and evaluated for in vitro cytotoxicity against THP-1, COLO-205, HCT-116, A549, HeLa, CAKI-I, PC-3, MiaPaca-2 human cancer cell lines. The results revealed that the compounds SA-1 to SA-9, SB-2, SB-3, SB-4, SB-7 and SC-2 showed a good range of IC50 values against THP-1, COLO-205, HCT-116 and PC-3 cell lines, while the other four cell lines among these were found to be almost resistant. Structure activity relationship revealed that the nature of Ring X and substitution at position R influences the activity. Methoxy substituted phenyl ring as Ring X and H as R were found to be the ideal structural features. The most potent compounds (SA-2, SA-3, SA-4, SA-7) were further tested for tubulin inhibition. Compound SA-2 was found to significantly inhibit the tubulin polymerization (IC50=1.2 μM against HCT-116). Compound SA-2, moreover, lead to the disruption of microtubules as confirmed by immunofluorescence technique. The significant cytotoxicity and tubulin inhibition by SA-2 was streamlined by molecular modeling studies where it was docked at the curcumin binding site of tubulin.
Collapse
Affiliation(s)
- Sahil Sharma
- Department of Pharmaceutical Sciences, Guru Nanak Dev University, Amritsar, Punjab 143005, India
| | - Manish K Gupta
- Lloyd Institute of Management and Technology, Greater Noida, UP, India
| | - Ajit K Saxena
- Indian Institute of Integrative Medicine, Jammu, India
| | - Preet Mohinder S Bedi
- Department of Pharmaceutical Sciences, Guru Nanak Dev University, Amritsar, Punjab 143005, India
| |
Collapse
|
275
|
Liu HC, Tang SZ, Lu S, Ran T, Wang J, Zhang YM, Xu AY, Lu T, Chen YD. Studies on [5,6]-Fused Bicyclic Scaffolds Derivatives as Potent Dual B-RafV600E/KDR Inhibitors Using Docking and 3D-QSAR Approaches. Int J Mol Sci 2015; 16:24451-74. [PMID: 26501259 PMCID: PMC4632759 DOI: 10.3390/ijms161024451] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/06/2015] [Revised: 09/22/2015] [Accepted: 10/07/2015] [Indexed: 01/07/2023] Open
Abstract
Research and development of multi-target inhibitors has attracted increasing attention as anticancer therapeutics. B-RafV600E synergistically works with vascular endothelial growth factor receptor 2 (KDR) to promote the occurrence and progression of cancers, and the development of dual-target drugs simultaneously against these two kinds of kinase may offer a better treatment advantage. In this paper, docking and three-dimensional quantitative structure activity relationship (3D-QSAR) studies were performed on a series of dual B-Raf/KDR inhibitors with a novel hinge-binding group, [5,6]-fused bicyclic scaffold. Docking studies revealed optimal binding conformations of these compounds interacting with both B-Raf and KDR. Based on these conformations, comparative molecular field analysis (CoMFA) and comparative molecular similarity indices analysis (CoMSIA) 3D-QSAR models were constructed, and the best CoMFA (q²=0.542, r²=0.989 for B-Raf; q²=0.768, r²=0.991 for KDR) and CoMSIA models (q²=0.519, r²=0.992 for B-Raf; q²=0.849, r²=0.993 for KDR) were generated. Further external validations confirmed their predictability, yielding satisfactory correlation coefficients (r²pred=0.764 (CoMFA), r²pred=0.841 (CoMSIA) for B-Raf, r²pred=0.912 (CoMFA), r²pred=0.846 (CoMSIA) for KDR, respectively). Through graphical analysis and comparison on docking results and 3D-QSAR contour maps, key amino acids that affect the ligand-receptor interactions were identified and structural features influencing the activities were discussed. New potent derivatives were designed, and subjected to preliminary pharmacological evaluation. The study may offer useful references for the modification and development of novel dual B-Raf/KDR inhibitors.
Collapse
Affiliation(s)
- Hai-Chun Liu
- School of Science, China Pharmaceutical University, Nanjing 211169, China.
| | - San-Zhi Tang
- School of Science, China Pharmaceutical University, Nanjing 211169, China.
| | - Shuai Lu
- School of Science, China Pharmaceutical University, Nanjing 211169, China.
| | - Ting Ran
- School of Science, China Pharmaceutical University, Nanjing 211169, China.
| | - Jian Wang
- School of Science, China Pharmaceutical University, Nanjing 211169, China.
| | - Yan-Min Zhang
- School of Science, China Pharmaceutical University, Nanjing 211169, China.
| | - An-Yang Xu
- School of Science, China Pharmaceutical University, Nanjing 211169, China.
| | - Tao Lu
- School of Science, China Pharmaceutical University, Nanjing 211169, China.
- State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 211169, China.
| | - Ya-Dong Chen
- School of Science, China Pharmaceutical University, Nanjing 211169, China.
| |
Collapse
|
276
|
Wang JW, Woodward DF, Martos JL, Cornell CL, Carling RW, Kingsley PJ, Marnett LJ. Multitargeting of selected prostanoid receptors provides agents with enhanced anti-inflammatory activity in macrophages. FASEB J 2015; 30:394-404. [PMID: 26420849 DOI: 10.1096/fj.15-275610] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/04/2015] [Accepted: 09/14/2015] [Indexed: 12/31/2022]
Abstract
A polypharmacologic approach to prostanoid based anti-inflammatory therapeutics was undertaken in order to exploit both the anti- and proinflammatory properties attributed to the various prostanoid receptors. Multitargeting of selected prostanoid receptors yielded a prototype compound, compound 1 (AGN 211377), that antagonizes prostaglandin D2 receptors (DPs) DP1 (49) and DP2 (558), prostaglandin E2 receptors (EPs) EP1 (266) and EP4 (117), prostaglandin F2α receptor (FP) (61), and thromboxane A2 receptor (TP) (11) while sparing EP2, EP3, and prostaglandin I2 receptors (IPs); Kb values (in nanomoles) are given in parentheses. Compound 1 evoked a pronounced inhibition of cytokine/chemokine secretion from lipopolysaccharide or TNF-α stimulated primary human macrophages. These cytokine/chemokines included cluster of designation 40 receptor (CD40), epithelial-derived neutrophil-activating protein 78 (ENA-78), granulocyte colony stimulating factor (G-CSF), granulocyte macrophage colony stimulating factor (GM-CSF), IL-8, IL-18, monocyte chemotactic protein-1 (CCL2) (MCP-1), tissue plasminogen activator inhibitor (PAI-1), and regulated on activation, normal T cell expressed and secreted (RANTES). In contrast, the inhibitory effects of most antagonists selective for a single receptor were modest or absent, and selective EP2 receptor blockade increased cytokine release in some instances. Compound 1 also showed clear superiority to the cyclooxygenase inhibitors diclofenac and rofecoxib. These findings reveal that blockade of multiple prostanoid receptors, with absent antagonism of EP2 and IP, may provide more effective anti-inflammatory activity than global suppression of prostanoid synthesis or highly selective prostanoid receptor blockade. These investigations demonstrate the first working example of prostanoid receptor polypharmacology for potentially safer and more effective anti-inflammatory therapeutics by blocking multiple proinflammatory receptors while sparing those with anti-inflammatory activity.
Collapse
Affiliation(s)
- Jenny W Wang
- *Department of Biological Sciences, Allergan, Incorporated, Irvine, California, USA; Department of Bioengineering, Imperial College London, London, United Kingdom; Drug Discovery Department, Selcia Limited, Ongar, United Kingdom; and Department of Biochemistry, Vanderbilt University School of Medicine, Nashville, Tennessee, USA
| | - David F Woodward
- *Department of Biological Sciences, Allergan, Incorporated, Irvine, California, USA; Department of Bioengineering, Imperial College London, London, United Kingdom; Drug Discovery Department, Selcia Limited, Ongar, United Kingdom; and Department of Biochemistry, Vanderbilt University School of Medicine, Nashville, Tennessee, USA
| | - Jose L Martos
- *Department of Biological Sciences, Allergan, Incorporated, Irvine, California, USA; Department of Bioengineering, Imperial College London, London, United Kingdom; Drug Discovery Department, Selcia Limited, Ongar, United Kingdom; and Department of Biochemistry, Vanderbilt University School of Medicine, Nashville, Tennessee, USA
| | - Clive L Cornell
- *Department of Biological Sciences, Allergan, Incorporated, Irvine, California, USA; Department of Bioengineering, Imperial College London, London, United Kingdom; Drug Discovery Department, Selcia Limited, Ongar, United Kingdom; and Department of Biochemistry, Vanderbilt University School of Medicine, Nashville, Tennessee, USA
| | - Robert W Carling
- *Department of Biological Sciences, Allergan, Incorporated, Irvine, California, USA; Department of Bioengineering, Imperial College London, London, United Kingdom; Drug Discovery Department, Selcia Limited, Ongar, United Kingdom; and Department of Biochemistry, Vanderbilt University School of Medicine, Nashville, Tennessee, USA
| | - Philip J Kingsley
- *Department of Biological Sciences, Allergan, Incorporated, Irvine, California, USA; Department of Bioengineering, Imperial College London, London, United Kingdom; Drug Discovery Department, Selcia Limited, Ongar, United Kingdom; and Department of Biochemistry, Vanderbilt University School of Medicine, Nashville, Tennessee, USA
| | - Lawrence J Marnett
- *Department of Biological Sciences, Allergan, Incorporated, Irvine, California, USA; Department of Bioengineering, Imperial College London, London, United Kingdom; Drug Discovery Department, Selcia Limited, Ongar, United Kingdom; and Department of Biochemistry, Vanderbilt University School of Medicine, Nashville, Tennessee, USA
| |
Collapse
|
277
|
Talevi A. Multi-target pharmacology: possibilities and limitations of the "skeleton key approach" from a medicinal chemist perspective. Front Pharmacol 2015; 6:205. [PMID: 26441661 PMCID: PMC4585027 DOI: 10.3389/fphar.2015.00205] [Citation(s) in RCA: 215] [Impact Index Per Article: 23.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2015] [Accepted: 09/04/2015] [Indexed: 11/23/2022] Open
Abstract
Multi-target drugs have raised considerable interest in the last decade owing to their advantages in the treatment of complex diseases and health conditions linked to drug resistance issues. Prospective drug repositioning to treat comorbid conditions is an additional, overlooked application of multi-target ligands. While medicinal chemists usually rely on some version of the lock and key paradigm to design novel therapeutics, modern pharmacology recognizes that the mid- and long-term effects of a given drug on a biological system may depend not only on the specific ligand-target recognition events but also on the influence of the repeated administration of a drug on the cell gene signature. The design of multi-target agents usually imposes challenging restrictions on the topology or flexibility of the candidate drugs, which are briefly discussed in the present article. Finally, computational strategies to approach the identification of novel multi-target agents are overviewed.
Collapse
Affiliation(s)
- Alan Talevi
- Medicinal Chemistry, Department of Biological Sciences, Faculty of Exact Sciences, National University of La Plata , La Plata, Argentina
| |
Collapse
|
278
|
Singh P, Kaur J, Singh G, Bhatti R. Triblock Conjugates: Identification of a Highly Potent Antiinflammatory Agent. J Med Chem 2015. [DOI: 10.1021/acs.jmedchem.5b00952] [Citation(s) in RCA: 36] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Affiliation(s)
- Palwinder Singh
- Department
of Chemistry, Guru Nanak Dev University, Amritsar, 143005, India
| | - Jagroop Kaur
- Department
of Chemistry, Guru Nanak Dev University, Amritsar, 143005, India
| | - Gurjit Singh
- Department of Pharmaceutical Sciences, Guru Nanak Dev University, Amritsar, 143005, India
| | - Rajbir Bhatti
- Department of Pharmaceutical Sciences, Guru Nanak Dev University, Amritsar, 143005, India
| |
Collapse
|
279
|
Wu H, Hu C, Wang A, Weisberg EL, Chen Y, Yun CH, Wang W, Liu Y, Liu X, Tian B, Wang J, Zhao Z, Liang Y, Li B, Wang L, Wang B, Chen C, Buhrlage SJ, Qi Z, Zou F, Nonami A, Li Y, Fernandes SM, Adamia S, Stone RM, Galinsky IA, Wang X, Yang G, Griffin JD, Brown JR, Eck MJ, Liu J, Gray NS, Liu Q. Discovery of a BTK/MNK dual inhibitor for lymphoma and leukemia. Leukemia 2015; 30:173-81. [PMID: 26165234 DOI: 10.1038/leu.2015.180] [Citation(s) in RCA: 35] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/09/2014] [Revised: 06/28/2015] [Accepted: 06/29/2015] [Indexed: 12/14/2022]
Abstract
Bruton's tyrosine kinase (BTK) kinase is a member of the TEC kinase family and is a key regulator of the B-cell receptor (BCR)-mediated signaling pathway. It is important for B-cell maturation, proliferation, survival and metastasis. Pharmacological inhibition of BTK is clinically effective against a variety of B-cell malignances, such as mantle cell lymphoma, chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML) and activated B-cell-diffuse large B-cell lymphoma. MNK kinase is one of the key downstream regulators in the RAF-MEK-ERK signaling pathway and controls protein synthesis via regulating the activity of eIF4E. Inhibition of MNK activity has been observed to moderately inhibit the proliferation of AML cells. Through a structure-based drug-design approach, we have discovered a selective and potent BTK/MNK dual kinase inhibitor (QL-X-138), which exhibits covalent binding to BTK and noncovalent binding to MNK. Compared with the BTK kinase inhibitor (PCI-32765) and the MNK kinase inhibitor (cercosporamide), QL-X-138 enhanced the antiproliferative efficacies in vitro against a variety of B-cell cancer cell lines, as well as AML and CLL primary patient cells, which respond moderately to BTK inhibitor in vitro. The agent can effectively arrest the growth of lymphoma and leukemia cells at the G0-G1 stage and can induce strong apoptotic cell death. These primary results demonstrate that simultaneous inhibition of BTK and MNK kinase activity might be a new therapeutic strategy for B-cell malignances.
Collapse
Affiliation(s)
- H Wu
- High Magnetic Field laboratory, Chinese Academy of Sciences, Hefei, Anhui, China.,University of Science and Technology of China, Anhui, Hefei, P. R. China
| | - C Hu
- High Magnetic Field laboratory, Chinese Academy of Sciences, Hefei, Anhui, China
| | - A Wang
- High Magnetic Field laboratory, Chinese Academy of Sciences, Hefei, Anhui, China.,University of Science and Technology of China, Anhui, Hefei, P. R. China
| | - E L Weisberg
- Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
| | - Y Chen
- High Magnetic Field laboratory, Chinese Academy of Sciences, Hefei, Anhui, China
| | - C-H Yun
- Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA
| | - W Wang
- High Magnetic Field laboratory, Chinese Academy of Sciences, Hefei, Anhui, China
| | - Y Liu
- Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
| | - X Liu
- High Magnetic Field laboratory, Chinese Academy of Sciences, Hefei, Anhui, China.,University of Science and Technology of China, Anhui, Hefei, P. R. China
| | - B Tian
- Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing Ophthalmology and Visual Science Key Laboratory, Beijing, China
| | - J Wang
- Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA
| | - Z Zhao
- High Magnetic Field laboratory, Chinese Academy of Sciences, Hefei, Anhui, China
| | - Y Liang
- Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA
| | - B Li
- High Magnetic Field laboratory, Chinese Academy of Sciences, Hefei, Anhui, China
| | - L Wang
- High Magnetic Field laboratory, Chinese Academy of Sciences, Hefei, Anhui, China
| | - B Wang
- High Magnetic Field laboratory, Chinese Academy of Sciences, Hefei, Anhui, China
| | - C Chen
- High Magnetic Field laboratory, Chinese Academy of Sciences, Hefei, Anhui, China
| | - S J Buhrlage
- Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA
| | - Z Qi
- High Magnetic Field laboratory, Chinese Academy of Sciences, Hefei, Anhui, China
| | - F Zou
- High Magnetic Field laboratory, Chinese Academy of Sciences, Hefei, Anhui, China
| | - A Nonami
- Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
| | - Y Li
- Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
| | - S M Fernandes
- Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
| | - S Adamia
- Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
| | - R M Stone
- Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
| | - I A Galinsky
- Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
| | - X Wang
- Department of Lymphoma, Sino-US Center for Lymphoma and Leukemia, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China
| | - G Yang
- Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
| | - J D Griffin
- Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
| | - J R Brown
- Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
| | - M J Eck
- Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA
| | - J Liu
- High Magnetic Field laboratory, Chinese Academy of Sciences, Hefei, Anhui, China
| | - N S Gray
- Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA
| | - Q Liu
- High Magnetic Field laboratory, Chinese Academy of Sciences, Hefei, Anhui, China.,University of Science and Technology of China, Anhui, Hefei, P. R. China.,Hefei Science Center, Chinese Academy of Sciences, Hefei, Anhui, China
| |
Collapse
|
280
|
Seo YH. Dual Inhibitors Against Topoisomerases and Histone Deacetylases. J Cancer Prev 2015; 20:85-91. [PMID: 26151040 PMCID: PMC4492363 DOI: 10.15430/jcp.2015.20.2.85] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/19/2015] [Revised: 06/01/2015] [Accepted: 06/01/2015] [Indexed: 12/13/2022] Open
Abstract
Topoisomerases and histone deacetylases (HDACs) are considered as important therapeutic targets for a wide range of cancers, due to their association with the initiation, proliferation and survival of cancer cells. Topoisomerases are involved in the cleavage and religation processes of DNA, while HDACs regulate a dynamic epigenetic modification of the lysine amino acid on various proteins. Extensive studies have been undertaken to discover small molecule inhibitor of each protein and thereby, several drugs have been transpired from this effort and successfully approved for clinical use. However, the inherent heterogeneity and multiple genetic abnormalities of cancers challenge the clinical application of these single targeted drugs. In order to overcome the limitations of a single target approach, a novel approach, simultaneously targeting topoisomerases and HDACs with a single molecule has been recently employed and attracted much attention of medicinal chemists in drug discovery. This review highlights the current studies on the discovery of dual inhibitors against topoisomerases and HDACs, provides their pharmacological aspects and advantages, and discusses the challenges and promise of the dual inhibitors.
Collapse
Affiliation(s)
- Young Ho Seo
- College of Pharmacy, Keimyung University, Daegu, Korea
| |
Collapse
|
281
|
Aksakal F, Shvets N, Dimoglo A. The study of dual COX-2/5-LOX inhibitors by using electronic-topological approach based on data on the ligand–receptor interactions. J Mol Graph Model 2015; 60:79-88. [DOI: 10.1016/j.jmgm.2015.06.006] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/04/2015] [Revised: 06/14/2015] [Accepted: 06/16/2015] [Indexed: 11/17/2022]
|
282
|
Gu J, Zhang X, Ma Y, Li N, Luo F, Cao L, Wang Z, Yuan G, Chen L, Xiao W, Xu X. Quantitative modeling of dose-response and drug combination based on pathway network. J Cheminform 2015; 7:19. [PMID: 26101547 PMCID: PMC4476235 DOI: 10.1186/s13321-015-0066-6] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2014] [Accepted: 04/14/2015] [Indexed: 12/12/2022] Open
Abstract
Background Quantitative description of dose–response of a drug for complex systems is essential for treatment of diseases and drug discovery. Given the growth of large-scale biological data obtained by multi-level assays, computational modeling has become an important approach to understand the mechanism of drug action. However, due to complicated interactions between drugs and cellular targets, the prediction of drug efficacy is a challenge, especially for complex systems. And the biological systems can be regarded as networks, where nodes represent molecular entities (DNA, RNA, protein and small compound) and processes, edges represent the relationships between nodes. Thus we combine biological pathway-based network modeling and molecular docking to evaluate drug efficacy. Results Network efficiency (NE) and network flux (NF) are both global measures of the network connectivity. In this work, we used NE and NF to quantitatively evaluate the inhibitory effects of compounds against the lipopolysaccharide-induced production of prostaglandin E2. The edge values of the pathway network of this biological process were reset according to the Michaelis-Menten equation, which used the binding constant and drug concentration to determine the degree of inhibition of the target protein in the pathway. The combination of NE and NF was adopted to evaluate the inhibitory effects. The dose–response curve was sigmoid and the EC50 values of 5 compounds were in good agreement with experimental results (R2 = 0.93). Moreover, we found that 2 drugs produced maximal synergism when they were combined according to the ratio between each EC50. Conclusions This quantitative model has the ability to predict the dose–response relationships of single drug and drug combination in the context of the pathway network of biological process. These findings are valuable for the evaluation of drug efficacy and thus provide an effective approach for pathway network-based drug discovery.
Collapse
Affiliation(s)
- Jiangyong Gu
- Beijing National Laboratory for Molecular Sciences (BNLMS), State Key Laboratory of Rare Earth Materials Chemistry and Applications, College of Chemistry and Molecular Engineering, Peking University, Beijing, 100871 People's Republic of China
| | - Xinzhuang Zhang
- Beijing National Laboratory for Molecular Sciences (BNLMS), State Key Laboratory of Rare Earth Materials Chemistry and Applications, College of Chemistry and Molecular Engineering, Peking University, Beijing, 100871 People's Republic of China.,National Key Laboratory of Pharmaceutical New Technology for Chinese Medicine, Kanion Pharmaceutical Corporation, Lianyungang City, 222002 People's Republic of China
| | - Yimin Ma
- National Key Laboratory of Pharmaceutical New Technology for Chinese Medicine, Kanion Pharmaceutical Corporation, Lianyungang City, 222002 People's Republic of China
| | - Na Li
- National Key Laboratory of Pharmaceutical New Technology for Chinese Medicine, Kanion Pharmaceutical Corporation, Lianyungang City, 222002 People's Republic of China
| | - Fang Luo
- Beijing National Laboratory for Molecular Sciences (BNLMS), State Key Laboratory of Rare Earth Materials Chemistry and Applications, College of Chemistry and Molecular Engineering, Peking University, Beijing, 100871 People's Republic of China
| | - Liang Cao
- National Key Laboratory of Pharmaceutical New Technology for Chinese Medicine, Kanion Pharmaceutical Corporation, Lianyungang City, 222002 People's Republic of China
| | - Zhenzhong Wang
- National Key Laboratory of Pharmaceutical New Technology for Chinese Medicine, Kanion Pharmaceutical Corporation, Lianyungang City, 222002 People's Republic of China
| | - Gu Yuan
- Beijing National Laboratory for Molecular Sciences (BNLMS), State Key Laboratory of Rare Earth Materials Chemistry and Applications, College of Chemistry and Molecular Engineering, Peking University, Beijing, 100871 People's Republic of China
| | - Lirong Chen
- Beijing National Laboratory for Molecular Sciences (BNLMS), State Key Laboratory of Rare Earth Materials Chemistry and Applications, College of Chemistry and Molecular Engineering, Peking University, Beijing, 100871 People's Republic of China
| | - Wei Xiao
- National Key Laboratory of Pharmaceutical New Technology for Chinese Medicine, Kanion Pharmaceutical Corporation, Lianyungang City, 222002 People's Republic of China
| | - Xiaojie Xu
- Beijing National Laboratory for Molecular Sciences (BNLMS), State Key Laboratory of Rare Earth Materials Chemistry and Applications, College of Chemistry and Molecular Engineering, Peking University, Beijing, 100871 People's Republic of China
| |
Collapse
|
283
|
Srivastava V, Lee H. Chloroquine-based hybrid molecules as promising novel chemotherapeutic agents. Eur J Pharmacol 2015; 762:472-86. [PMID: 25959387 DOI: 10.1016/j.ejphar.2015.04.048] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/10/2015] [Revised: 04/15/2015] [Accepted: 04/20/2015] [Indexed: 12/11/2022]
Abstract
Chloroquine (CQ) has a broad spectrum of pharmacological activities including anticancer and anti-inflammatory, in addition to its well-known antimalarial activity. This very useful property of CQ may be rendered through a variety of different molecular and cellular mechanisms, including the induction of apoptosis, necrosis and lysosomal dysfunction. CQ alone may not be as effective as many well-known anticancer drugs; however, it often shows synergisticts when combined with other anticancer agents, without causing substantial ill-effects. To increase its pharmacological activity, scientists synthesized many different chloroquine derivatives by a repositioning approach, some of which show higher activities than the parental CQ. To further improve anticancer activity, medicinal chemists have recently been focusing on generating CQ hybrid molecules by joining, directly or through a linker, 4-aminoquinoline and other pharmacologically active phamarcophore(s). Indeed, some CQ hybrid molecules substantially improved anticancer activity while maintaining desirable CQ property, providing an excellent opportunity of developing effective and safe novel anticancer agents. Since the approach of developing CQ hybrid molecules has advanced much more in the antimalarial drug research, it can provide an excellent template for anticancer drug development. This review provides an overview of CQ-based hybrid molecules by focusing on: (1) the potential advantage of the hybrid approach in developing effective and safe anticancer agents; (2) what we can learn from the CQ hybrid approach used in the development of effective antimalarial agents; and (3) CQ hybrid molecules as potential anticancer agents in different categories classified based on their chemical compositions.
Collapse
Affiliation(s)
- Vandana Srivastava
- Advanced Medical Research Institute of Canada, Health Sciences North, 41 Ramsey Lake Road, Sudbury, Ontario, Canada P3E 5J1; Division of Medical Sciences, Northern Ontario School of Medicine, 935 Ramsey Lake Road, Sudbury, Ontario, Canada P3E 2C6
| | - Hoyun Lee
- Advanced Medical Research Institute of Canada, Health Sciences North, 41 Ramsey Lake Road, Sudbury, Ontario, Canada P3E 5J1; Division of Medical Sciences, Northern Ontario School of Medicine, 935 Ramsey Lake Road, Sudbury, Ontario, Canada P3E 2C6.
| |
Collapse
|
284
|
Nitric oxide donors and selective carbonic anhydrase inhibitors: a dual pharmacological approach for the treatment of glaucoma, cancer and osteoporosis. Molecules 2015; 20:5667-79. [PMID: 25838170 PMCID: PMC6272217 DOI: 10.3390/molecules20045667] [Citation(s) in RCA: 32] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2015] [Revised: 03/15/2015] [Accepted: 03/24/2015] [Indexed: 11/17/2022] Open
Abstract
Due to the recognized biological role of nitric oxide (NO) donating derivatives and of selective inhibitors of specific human carbonic anhydrase isoforms (CA, EC 4.2.1.1), promising compounds having an aromatic/heterocyclic primary sulfonamide and functionalized with NO-releasing moieties have been designed. These bifunctional agents have been tested in vitro and in vivo to assess their dual pharmacological activity. According to the encouraging results they could be proposed for the treatment of angle-open glaucoma, cancer regression and osteoporosis, in which both NO and CA activities are involved.
Collapse
|
285
|
Rochais C, Lecoutey C, Gaven F, Giannoni P, Hamidouche K, Hedou D, Dubost E, Genest D, Yahiaoui S, Freret T, Bouet V, Dauphin F, Sopkova de Oliveira Santos J, Ballandonne C, Corvaisier S, Malzert-Fréon A, Legay R, Boulouard M, Claeysen S, Dallemagne P. Novel multitarget-directed ligands (MTDLs) with acetylcholinesterase (AChE) inhibitory and serotonergic subtype 4 receptor (5-HT4R) agonist activities as potential agents against Alzheimer's disease: the design of donecopride. J Med Chem 2015; 58:3172-87. [PMID: 25793650 DOI: 10.1021/acs.jmedchem.5b00115] [Citation(s) in RCA: 85] [Impact Index Per Article: 9.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/14/2023]
Abstract
In this work, we describe the synthesis and in vitro evaluation of a novel series of multitarget-directed ligands (MTDL) displaying both nanomolar dual-binding site (DBS) acetylcholinesterase inhibitory effects and partial 5-HT4R agonist activity, among which donecopride was selected for further in vivo evaluations in mice. The latter displayed procognitive and antiamnesic effects and enhanced sAPPα release, accounting for a potential symptomatic and disease-modifying therapeutic benefit in the treatment of Alzheimer's disease.
Collapse
Affiliation(s)
- Christophe Rochais
- †UNICAEN, CERMN (Centre d'Etudes et de Recherche sur le Médicament de Normandie), F-14032 Caen, France
| | - Cédric Lecoutey
- †UNICAEN, CERMN (Centre d'Etudes et de Recherche sur le Médicament de Normandie), F-14032 Caen, France
| | - Florence Gaven
- ‡CNRS, UMR-5203, Institut de Génomique Fonctionnelle, F-34000 Montpellier, France.,§Inserm, U1191, F-34000 Montpellier, France.,∥Université de Montpellier, UMR-5203, F-34000 Montpellier, France
| | - Patrizia Giannoni
- ‡CNRS, UMR-5203, Institut de Génomique Fonctionnelle, F-34000 Montpellier, France.,§Inserm, U1191, F-34000 Montpellier, France.,∥Université de Montpellier, UMR-5203, F-34000 Montpellier, France
| | - Katia Hamidouche
- ⊥UNICAEN, GMPc5 (Groupe Mémoire et Plasticité comportementale), F-14032 Caen, France
| | - Damien Hedou
- †UNICAEN, CERMN (Centre d'Etudes et de Recherche sur le Médicament de Normandie), F-14032 Caen, France
| | - Emmanuelle Dubost
- †UNICAEN, CERMN (Centre d'Etudes et de Recherche sur le Médicament de Normandie), F-14032 Caen, France
| | - David Genest
- †UNICAEN, CERMN (Centre d'Etudes et de Recherche sur le Médicament de Normandie), F-14032 Caen, France
| | - Samir Yahiaoui
- †UNICAEN, CERMN (Centre d'Etudes et de Recherche sur le Médicament de Normandie), F-14032 Caen, France
| | - Thomas Freret
- ⊥UNICAEN, GMPc5 (Groupe Mémoire et Plasticité comportementale), F-14032 Caen, France
| | - Valentine Bouet
- ⊥UNICAEN, GMPc5 (Groupe Mémoire et Plasticité comportementale), F-14032 Caen, France
| | - François Dauphin
- ⊥UNICAEN, GMPc5 (Groupe Mémoire et Plasticité comportementale), F-14032 Caen, France
| | | | - Céline Ballandonne
- †UNICAEN, CERMN (Centre d'Etudes et de Recherche sur le Médicament de Normandie), F-14032 Caen, France
| | - Sophie Corvaisier
- †UNICAEN, CERMN (Centre d'Etudes et de Recherche sur le Médicament de Normandie), F-14032 Caen, France.,⊥UNICAEN, GMPc5 (Groupe Mémoire et Plasticité comportementale), F-14032 Caen, France
| | - Aurélie Malzert-Fréon
- †UNICAEN, CERMN (Centre d'Etudes et de Recherche sur le Médicament de Normandie), F-14032 Caen, France
| | - Remi Legay
- †UNICAEN, CERMN (Centre d'Etudes et de Recherche sur le Médicament de Normandie), F-14032 Caen, France
| | - Michel Boulouard
- ⊥UNICAEN, GMPc5 (Groupe Mémoire et Plasticité comportementale), F-14032 Caen, France
| | - Sylvie Claeysen
- ‡CNRS, UMR-5203, Institut de Génomique Fonctionnelle, F-34000 Montpellier, France.,§Inserm, U1191, F-34000 Montpellier, France.,∥Université de Montpellier, UMR-5203, F-34000 Montpellier, France
| | - Patrick Dallemagne
- †UNICAEN, CERMN (Centre d'Etudes et de Recherche sur le Médicament de Normandie), F-14032 Caen, France
| |
Collapse
|
286
|
Design and Synthesis of Novel Hybrid Molecules against Malaria. INTERNATIONAL JOURNAL OF MEDICINAL CHEMISTRY 2015; 2015:458319. [PMID: 25734014 PMCID: PMC4334980 DOI: 10.1155/2015/458319] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 09/08/2014] [Revised: 12/05/2014] [Accepted: 12/10/2014] [Indexed: 01/26/2023]
Abstract
The effective treatment of malaria can be very complex: Plasmodium parasites develop in multiple stages within a complex life cycle between mosquitoes as vectors and vertebrates as hosts. For the full and effective elimination of parasites, an effective drug should be active against the earliest stages of the Plasmodium infection: liver stages (reduce the progress of the infection), blood stages (cure the clinical symptoms), and gametocytes (inhibit the transmission cycle). Towards this goal, here we report the design, the synthetic methodology, and the characterization of novel hybrid agents with combined activity against Plasmodium liver stages and blood stages and gametocytes. The divergent synthetic approach allows the access to differently linked primaquine-chloroquine hybrid templates in up to eight steps.
Collapse
|
287
|
Geary TG, Sakanari JA, Caffrey CR. Anthelmintic drug discovery: into the future. J Parasitol 2015; 101:125-33. [PMID: 25584662 DOI: 10.1645/14-703.1] [Citation(s) in RCA: 76] [Impact Index Per Article: 8.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
Abstract
The last half-century has provided all of the (few) drugs currently used to treat human helminthiases. Concern regarding the long-term utility of these drugs, given how readily resistance evolves in the veterinary-agricultural sector, spurs the discovery of new chemical entities. We review the approaches and technologies in use to identify anthelmintics and discuss a number of drug discovery paradigms that may prove pivotal to the next half-century of anthelmintic development.
Collapse
Affiliation(s)
- Timothy G Geary
- Institute of Parasitology, McGill University, 21,111 Lakeshore Road, Ste. Anne de Bellevue, Quebec, Canada H9X 3V9
| | | | | |
Collapse
|
288
|
Bansal Y, Kaur M, Silakari O. Benzimidazole–ibuprofen/mesalamine conjugates: Potential candidates for multifactorial diseases. Eur J Med Chem 2015; 89:671-82. [DOI: 10.1016/j.ejmech.2014.10.081] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/23/2014] [Revised: 09/22/2014] [Accepted: 10/29/2014] [Indexed: 12/23/2022]
|
289
|
Jin Y, Cheng X, Yang F, Fu L. Ultracentrifugation-based multi-target affinity selection mass spectrometry. RSC Adv 2015. [DOI: 10.1039/c5ra22983a] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
A rate-zonal density gradient ultracentrifugation-based affinity selection mass spectrometry approach has been developed for simultaneous multi-target screening.
Collapse
Affiliation(s)
- Yan Jin
- School of Pharmacy
- Shanghai Jiao Tong University
- Shanghai 200240
- PR China
| | - Xueheng Cheng
- DMPK & Bioanalysis
- Vivo Biotech Ltd
- Shanghai 201203
- China
| | - Fengzhi Yang
- School of Pharmacy
- Shanghai Jiao Tong University
- Shanghai 200240
- PR China
| | - Lei Fu
- School of Pharmacy
- Shanghai Jiao Tong University
- Shanghai 200240
- PR China
| |
Collapse
|
290
|
Costa FN, da Silva TF, Silva EMB, Barroso RCR, Braz D, Barreiro EJ, Lima LM, Punzo F, Ferreira FF. Structural feature evolution – from fluids to the solid phase – and crystal morphology study of LASSBio 1601: a cyclohexyl-N-acylhydrazone derivative. RSC Adv 2015. [DOI: 10.1039/c5ra02696b] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022] Open
Abstract
Synthesis and structural characterization of LASSBIO 1601: a cyclohexyl-N-acylhydrazone derivative.
Collapse
Affiliation(s)
- Fanny Nascimento Costa
- Centro de Ciências Naturais e Humanas (CCNH)
- Universidade Federal do ABC (UFABC)
- Santo André
- Brazil
| | - Tiago F. da Silva
- LASSBio
- Institute of Biomedical Sciences
- Federal University of Rio de Janeiro (UFRJ)
- Rio de Janeiro
- Brazil
| | - Eduardo Miguez B. Silva
- Macromolecules Institute (IMA)
- Federal University of Rio de Janeiro (UFRJ)
- Rio de Janeiro
- Brazil
| | | | - Delson Braz
- Program of Nuclear Engineering (PEN/COPPE)
- Federal University of Rio de Janeiro (UFRJ)
- Rio de Janeiro
- Brazil
| | - Eliezer J. Barreiro
- LASSBio
- Institute of Biomedical Sciences
- Federal University of Rio de Janeiro (UFRJ)
- Rio de Janeiro
- Brazil
| | - Lídia Moreira Lima
- LASSBio
- Institute of Biomedical Sciences
- Federal University of Rio de Janeiro (UFRJ)
- Rio de Janeiro
- Brazil
| | - Francesco Punzo
- Dipartimento di Scienze del Farmaco
- Sezione Chimica
- Università degli Studi di Catania
- Catania 95125
- Italy
| | - Fabio Furlan Ferreira
- Centro de Ciências Naturais e Humanas (CCNH)
- Universidade Federal do ABC (UFABC)
- Santo André
- Brazil
| |
Collapse
|
291
|
Chen Y, Lan Y, Cao X, Xu X, Zhang J, Yu M, Liu X, Liu BF, Zhang G. Synthesis and evaluation of amide, sulfonamide and urea – benzisoxazole derivatives as potential atypical antipsychotics. MEDCHEMCOMM 2015. [DOI: 10.1039/c4md00578c] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
A series of amide derivatives of benzisoxazole has been synthesized and the target compounds evaluated for atypical antipsychotic activity in vitro and vivo.
Collapse
Affiliation(s)
- Yin Chen
- Systems Biology Theme
- Department of Biomedical Engineering
- College of Life Science and Technology
- Huazhong University of Science and Technology
- Wuhan 430074
| | - Yu Lan
- Systems Biology Theme
- Department of Biomedical Engineering
- College of Life Science and Technology
- Huazhong University of Science and Technology
- Wuhan 430074
| | - Xudong Cao
- Systems Biology Theme
- Department of Biomedical Engineering
- College of Life Science and Technology
- Huazhong University of Science and Technology
- Wuhan 430074
| | | | - Juecheng Zhang
- Systems Biology Theme
- Department of Biomedical Engineering
- College of Life Science and Technology
- Huazhong University of Science and Technology
- Wuhan 430074
| | - Minquan Yu
- Jiangsu Nhwa Pharmaceutical Co., Ltd
- Xuzhou
- China
| | - Xin Liu
- Systems Biology Theme
- Department of Biomedical Engineering
- College of Life Science and Technology
- Huazhong University of Science and Technology
- Wuhan 430074
| | - Bi-Feng Liu
- Systems Biology Theme
- Department of Biomedical Engineering
- College of Life Science and Technology
- Huazhong University of Science and Technology
- Wuhan 430074
| | - Guisen Zhang
- Systems Biology Theme
- Department of Biomedical Engineering
- College of Life Science and Technology
- Huazhong University of Science and Technology
- Wuhan 430074
| |
Collapse
|
292
|
Sanina NA, Aldoshin SM, Shmatko NY, Korchagin DV, Shilov GV, Knyazkina EV, Ovanesyan NS, Kulikov AV. Nitrosyl iron complexes with enhanced NO donating ability: synthesis, structure and properties of a new type of salt with the DNIC cations [Fe(SC(NH2)2)2(NO)2]+. NEW J CHEM 2015. [DOI: 10.1039/c4nj01693a] [Citation(s) in RCA: 29] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
A new structural type of water-soluble iron nitrosyl complexes with thiocarbamide has been obtained.
Collapse
Affiliation(s)
- Nataliya A. Sanina
- Institute of Problems of Chemical Physics
- Russian Academy of Sciences
- 142432 Chernogolovka
- Russia
| | - Sergey M. Aldoshin
- Institute of Problems of Chemical Physics
- Russian Academy of Sciences
- 142432 Chernogolovka
- Russia
| | - Natal'ya Yu. Shmatko
- Institute of Problems of Chemical Physics
- Russian Academy of Sciences
- 142432 Chernogolovka
- Russia
| | - Denis V. Korchagin
- Institute of Problems of Chemical Physics
- Russian Academy of Sciences
- 142432 Chernogolovka
- Russia
| | - Gennadii V. Shilov
- Institute of Problems of Chemical Physics
- Russian Academy of Sciences
- 142432 Chernogolovka
- Russia
| | | | - Nikolay S. Ovanesyan
- Institute of Problems of Chemical Physics
- Russian Academy of Sciences
- 142432 Chernogolovka
- Russia
| | - Alexander V. Kulikov
- Institute of Problems of Chemical Physics
- Russian Academy of Sciences
- 142432 Chernogolovka
- Russia
| |
Collapse
|
293
|
Jörg M, May LT, Mak FS, Lee KCK, Miller ND, Scammells PJ, Capuano B. Synthesis and pharmacological evaluation of dual acting ligands targeting the adenosine A2A and dopamine D2 receptors for the potential treatment of Parkinson's disease. J Med Chem 2014; 58:718-38. [PMID: 25490054 DOI: 10.1021/jm501254d] [Citation(s) in RCA: 40] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
A relatively new strategy in drug discovery is the development of dual acting ligands. These molecules are potentially able to interact at two orthosteric binding sites of a heterodimer simultaneously, possibly resulting in enhanced subtype selectivity, higher affinity, enhanced or modified physiological response, and reduced reliance on multiple drug administration regimens. In this study, we have successfully synthesized a series of classical heterobivalent ligands as well as a series of more integrated and "drug-like" dual acting molecules, incorporating ropinirole as a dopamine D2 receptor agonist and ZM 241385 as an adenosine A2A receptor antagonist. The best compounds of our series maintained the potency of the original pharmacophores at both receptors (adenosine A2A and dopamine D2). In addition, the integrated dual acting ligands also showed promising results in preliminary blood-brain barrier permeability tests, whereas the classical heterobivalent ligands are potentially more suited as pharmacological tools.
Collapse
Affiliation(s)
- Manuela Jörg
- Medicinal Chemistry and ‡Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences , 381 Royal Parade, Parkville, Victoria 3052, Australia
| | | | | | | | | | | | | |
Collapse
|
294
|
Teiten MH, Dicato M, Diederich M. Hybrid curcumin compounds: a new strategy for cancer treatment. Molecules 2014; 19:20839-63. [PMID: 25514225 PMCID: PMC6271749 DOI: 10.3390/molecules191220839] [Citation(s) in RCA: 78] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/09/2014] [Revised: 11/26/2014] [Accepted: 11/27/2014] [Indexed: 01/09/2023] Open
Abstract
Cancer is a multifactorial disease that requires treatments able to target multiple intracellular components and signaling pathways. The natural compound, curcumin, was already described as a promising anticancer agent due to its multipotent properties and huge amount of molecular targets in vitro. Its translation to the clinic is, however, limited by its reduced solubility and bioavailability in patients. In order to overcome these pharmacokinetic deficits of curcumin, several strategies, such as the design of synthetic analogs, the combination with specific adjuvants or nano-formulations, have been developed. By taking into account the risk-benefit profile of drug combinations, as well as the knowledge about curcumin's structure-activity relationship, a new concept for the combination of curcumin with scaffolds from different natural products or components has emerged. The concept of a hybrid curcumin molecule is based on the incorporation or combination of curcumin with specific antibodies, adjuvants or other natural products already used or not in conventional chemotherapy, in one single molecule. The high diversity of such conjugations enhances the selectivity and inherent biological activities and properties, as well as the efficacy of the parental compound, with particular emphasis on improving the efficacy of curcumin for future clinical treatments.
Collapse
Affiliation(s)
- Marie-Hélène Teiten
- Laboratory of Molecular and Cellular Biology of Cancer (LBMCC), Hôpital Kirchberg, 9, Rue Edward Steichen, Luxembourg L-2540, Luxembourg.
| | - Mario Dicato
- Laboratory of Molecular and Cellular Biology of Cancer (LBMCC), Hôpital Kirchberg, 9, Rue Edward Steichen, Luxembourg L-2540, Luxembourg.
| | - Marc Diederich
- Department of Pharmacy, College of Pharmacy, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul 151-742, Korea.
| |
Collapse
|
295
|
Peperidou A, Kapoukranidou D, Kontogiorgis C, Hadjipavlou-Litina D. Multitarget molecular hybrids of cinnamic acids. Molecules 2014; 19:20197-226. [PMID: 25474291 PMCID: PMC6271731 DOI: 10.3390/molecules191220197] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2014] [Revised: 11/14/2014] [Accepted: 11/25/2014] [Indexed: 11/18/2022] Open
Abstract
In an attempt to synthesize potential new multitarget agents, 11 novel hybrids incorporating cinnamic acids and paracetamol, 4-/7-hydroxycoumarin, benzocaine, p-aminophenol and m-aminophenol were synthesized. Three hybrids—2e, 2a, 2g—and 3b were found to be multifunctional agents. The hybrid 2e derived from the phenoxyphenyl cinnamic acid and m-acetamidophenol showed the highest lipoxygenase (LOX) inhibition and analgesic activity (IC50 = 0.34 μM and 98.1%, whereas the hybrid 3b of bromobenzyloxycinnamic acid and hymechromone exhibited simultaneously good LOX inhibitory activity (IC50 = 50 μM) and the highest anti-proteolytic activity (IC50= 5 μM). The hybrid 2a of phenyloxyphenyl acid with paracetamol showed a high analgesic activity (91%) and appears to be a promising agent for treating peripheral nerve injuries. Hybrid 2g which has an ester and an amide bond presents an interesting combination of anti-LOX and anti-proteolytic activity. The esters were found very potent and especially those derived from paracetamol and m-acetamidophenol. The amides follow. Based on 2D-structure–activity relationships it was observed that both steric and electronic parameters play major roles in the activity of these compounds. Molecular docking studies point to the fact that allosteric interactions might govern the LOX-inhibitor binding.
Collapse
Affiliation(s)
- Aikaterini Peperidou
- Department of Pharmaceutical Chemistry, School of Pharmacy, Faculty of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki 54124, Greece.
| | - Dorothea Kapoukranidou
- Department of Physiology, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki 54124, Greece.
| | - Christos Kontogiorgis
- Laboratory of Hygiene and Environmental Protection, Medical School, Democritus University of Thrace, Dragana (Campus), Alexandroupolis 68100, Greece.
| | - Dimitra Hadjipavlou-Litina
- Department of Pharmaceutical Chemistry, School of Pharmacy, Faculty of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki 54124, Greece.
| |
Collapse
|
296
|
Koeberle A, Werz O. Multi-target approach for natural products in inflammation. Drug Discov Today 2014; 19:1871-82. [DOI: 10.1016/j.drudis.2014.08.006] [Citation(s) in RCA: 192] [Impact Index Per Article: 19.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2014] [Revised: 07/11/2014] [Accepted: 08/20/2014] [Indexed: 12/30/2022]
|
297
|
Abstract
BACKGROUND The history of discovery of analgesic drugs has followed a trajectory from original serendipitous discovery of plant-derived substances to laboratory creation of customized molecules that are intentionally designed to interact with specific receptors of neurotransmitters involved in either the transmission of the pain signal or the attenuation of such a signal. The drugs most recently developed have been designed to provide incremental greater separation between pain relief and adverse effects. The result has been drugs that have individualized pharmacodynamic and pharmacokinetic characteristics that represent specific advances in basic science and translate into unique clinical profiles. Several of the drugs include non-opioid components. They retain some of the features of opioids, but have distinct clinical characteristics that differentiate them from traditional opioids. Thus they defy simple classification as opioids. SCOPE A summary is provided of the development of the modern view of multi-mechanistic pain and its treatment using analgesics that have multi-mechanisms of action (consisting of both opioid and non-opioid components). Descriptions of examples of such current analgesics and of those that have pharmacokinetic characteristics that result in atypical opioid clinical profiles are given. FINDINGS By serendipity or design, several current strong analgesics have opioid components of action, but have an additional non-opioid mechanism of action or some pharmacokinetic feature that gives them an atypical opioid clinical profile and renders them not easily classified as classical opioids. CONCLUSION An appreciation that there are now opioid analgesics that differentiate from classical opioids in ways that defy their simplistic classification as opioids suggests that recognition of subclasses of opioid analgesics would be more accurate scientifically and would be more informative for healthcare providers and regulators. This would likely lead to positive outcomes for the clinical use and regulatory control of the current drugs, and provide direction/strategy for the discovery of new drugs.
Collapse
Affiliation(s)
- Robert B Raffa
- Temple University School of Pharmacy , Philadelphia, PA , USA
| |
Collapse
|
298
|
Giacomini E, Nebbioso A, Ciotta A, Ianni C, Falchi F, Roberti M, Tolomeo M, Grimaudo S, Cristina A, Pipitone RM, Altucci L, Recanatini M. Novel antiproliferative chimeric compounds with marked histone deacetylase inhibitory activity. ACS Med Chem Lett 2014; 5:973-8. [PMID: 25221651 PMCID: PMC4160757 DOI: 10.1021/ml5000959] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/04/2014] [Accepted: 07/07/2014] [Indexed: 12/30/2022] Open
Abstract
Given our interest in finding potential antitumor agents and in view of the multifactorial mechanistic nature of cancer, in the present work, taking advantage of the multifunctional ligands approach, new chimeric molecules were designed and synthesized by combining in single chemical entities structural features of SAHA, targeting histone deacetylases (HDACs), with substituted stilbene or terphenyl derivatives previously obtained by us and endowed with antiproliferative and pro-apoptotic activity. The new chimeric derivatives were characterized with respect to their cytotoxic activity and their effects on cell cycle progression on different tumor cell lines, as well as their HDACs inhibition. Among the other, trans -6 showed the most interesting biological profile, as it exhibited a strong pro-apoptotic activity in tumor cell lines in comparison with both of its parent compounds and a marked HDAC inhibition.
Collapse
Affiliation(s)
- Elisa Giacomini
- Department
of Pharmacy and Biotechnology, University
of Bologna, Via Belmeloro
6, 40126 Bologna, Italy
- Department of Drug Discovery and Development, Italian Institute of Technology, Via Morego 30, 16163 Genova, Italy
| | - Angela Nebbioso
- Department of Biochemistry,
Biophysics and General Pathology, Second
University of Naples, Vico L. De Crecchio 7, 80138 Naples, Italy
| | - Alfonso Ciotta
- Department of Biochemistry,
Biophysics and General Pathology, Second
University of Naples, Vico L. De Crecchio 7, 80138 Naples, Italy
| | - Cristina Ianni
- Department
of Pharmacy and Biotechnology, University
of Bologna, Via Belmeloro
6, 40126 Bologna, Italy
| | - Federico Falchi
- Department
of Pharmacy and Biotechnology, University
of Bologna, Via Belmeloro
6, 40126 Bologna, Italy
- Department of Drug Discovery and Development, Italian Institute of Technology, Via Morego 30, 16163 Genova, Italy
| | - Marinella Roberti
- Department
of Pharmacy and Biotechnology, University
of Bologna, Via Belmeloro
6, 40126 Bologna, Italy
| | - Manlio Tolomeo
- Interdepartmental
Center of Research in Clinical Oncology and Department of Infectious
Diseases, University of Palermo, Via del Vespro 129, 90127 Palermo, Italy
| | - Stefania Grimaudo
- DiBiMIS, Laboratory of Molecular Pathology, Institute
of Gastroenterology, University of Palermo, Piazza delle Cliniche 2, 90127 Palermo, Italy
| | - Antonietta
Di Cristina
- DiBiMIS, Laboratory of Molecular Pathology, Institute
of Gastroenterology, University of Palermo, Piazza delle Cliniche 2, 90127 Palermo, Italy
| | - Rosaria Maria Pipitone
- DiBiMIS, Laboratory of Molecular Pathology, Institute
of Gastroenterology, University of Palermo, Piazza delle Cliniche 2, 90127 Palermo, Italy
| | - Lucia Altucci
- Department of Biochemistry,
Biophysics and General Pathology, Second
University of Naples, Vico L. De Crecchio 7, 80138 Naples, Italy
- Institute of Genetics and Biophysics, IGB, Via Pietro Castellino 111, 80131 Naples, Italy
| | - Maurizio Recanatini
- Department
of Pharmacy and Biotechnology, University
of Bologna, Via Belmeloro
6, 40126 Bologna, Italy
| |
Collapse
|
299
|
Geppert T, Koeppen H. Biological Networks and Drug Discovery-Where Do We Stand? Drug Dev Res 2014; 75:271-82. [DOI: 10.1002/ddr.21207] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Affiliation(s)
- Tim Geppert
- Lead Identification and Optimization Support; Boehringer Ingelheim Pharma GmbH & Co. KG; Biberach/Riss 88397 Germany
| | - Herbert Koeppen
- Lead Identification and Optimization Support; Boehringer Ingelheim Pharma GmbH & Co. KG; Biberach/Riss 88397 Germany
| |
Collapse
|
300
|
Pei J, Yin N, Ma X, Lai L. Systems Biology Brings New Dimensions for Structure-Based Drug Design. J Am Chem Soc 2014; 136:11556-65. [DOI: 10.1021/ja504810z] [Citation(s) in RCA: 64] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Affiliation(s)
- Jianfeng Pei
- Center
for Quantitative Biology, Academy for Advanced Interdisciplinary Studies, Peking University, Beijing 100871, China
| | - Ning Yin
- Center
for Quantitative Biology, Academy for Advanced Interdisciplinary Studies, Peking University, Beijing 100871, China
| | - Xiaomin Ma
- Center
for Quantitative Biology, Academy for Advanced Interdisciplinary Studies, Peking University, Beijing 100871, China
| | - Luhua Lai
- Center
for Quantitative Biology, Academy for Advanced Interdisciplinary Studies, Peking University, Beijing 100871, China
- Beijing
National Laboratory for Molecular Science, State Key Laboratory for
Structural Chemistry of Unstable and Stable Species, College of Chemistry
and Molecular Engineering, Peking University, Beijing 100871, China
- Peking-Tsinghua
Center for Life Sciences, Peking University, Beijing 100871, China
| |
Collapse
|